# Americans support cannabis rescheduling, study finds – EurekAlert! > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-rescheduling-clinical-implications-healthcare-providers/ > **Published:** 2026-05-20T00:24:20-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:06:00-04:00 > **Clinical Summary:** Clinical analysis of cannabis rescheduling implications for healthcare providers, patient care, and medical research from leading cannabis medicine expert. --- CED Clinical Relevance  #60Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Policy[Patient Education](https://cedclinic.com/medical-cannabis-patient-education-basics/)Evidence & Regulation[Clinical Practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) Why This Matters Public support for cannabis rescheduling reflects growing recognition of therapeutic potential, which may influence [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) environment and patient expectations. Understanding the gap between public opinion and regulatory status is relevant for clinicians navigating cannabis discussions with informed patients. Clinical Summary A recent survey documents substantial public support for cannabis rescheduling from its current Schedule I status. This finding reflects broader shifts in how Americans view cannabis—both as a potential medicine and in terms of legal access. The data itself does not evaluate efficacy or safety; it measures perception and policy preference among the general population. Dr. Caplan’s Take “Public opinion and [clinical evidence](https://cedclinic.com/academic-partnerships-cannabis-research/) are not the same thing. What matters in my practice is what the peer-reviewed literature actually shows about efficacy and harm for specific conditions—and there, the evidence is still incomplete. Rescheduling may ease research, which would be clinically valuable.” Clinical Perspective 🧠 Clinicians should be prepared for patients citing public support or regulatory momentum as reasons to use cannabis. The clinical conversation remains the same: what condition are we treating, what does the evidence show, what are the risks for this specific patient, and are there alternatives? Rescheduling discussions are policy-level; dosing and patient selection remain clinical-level. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Americans%20support%20cannabis%20rescheduling%2C%20study%20finds%20-%20EurekAlert%21%20%40drcaplan&url=https%3A//www.eurekalert.org/news-releases/1126170)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.eurekalert.org/news-releases/1126170)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Americans%20support%20cannabis%20rescheduling%2C%20study%20finds%20-%20EurekAlert%21%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.eurekalert.org/news-releases/1126170)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.eurekalert.org/news-releases/1126170](https://www.eurekalert.org/news-releases/1126170) Table of Contents - [FAQ](#FAQ)[What is CED Clinical Relevance #60?](#What_is_CED_Clinical_Relevance_60) - [What topics does this article cover?](#What_topics_does_this_article_cover) - [Who should be interested in this content?](#Who_should_be_interested_in_this_content) - [What is the significance of the “Notable Clinical Interest” designation?](#What_is_the_significance_of_the_Notable_Clinical_Interest_designation) - [Where does this information come from?](#Where_does_this_information_come_from) - [Related](#Related) ## FAQ #### What is CED Clinical Relevance #60? CED Clinical Relevance #60 is a notable clinical interest alert highlighting emerging findings or policy developments in cannabis and medical practice. It has been designated as worth monitoring closely by clinical professionals. #### What topics does this article cover? This article covers multiple interconnected areas including cannabis policy, [patient education](https://cedclinic.com/medical-cannabis-patient-education-basics/), evidence and regulation, and [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). The comprehensive approach ensures coverage of relevant clinical and regulatory considerations. #### Who should be interested in this content? This content is relevant for healthcare providers, clinical practitioners, policymakers, and patients interested in cannabis-related medical developments. The multi-disciplinary tags suggest applicability across various healthcare settings and specialties. #### What is the significance of the “Notable Clinical Interest” designation? The “Notable Clinical Interest” designation indicates that this information represents emerging findings or policy developments that [healthcare professionals](https://cedclinic.com/women-reproductive-health-cannabis-applications/) should actively monitor. It signals potential importance for clinical decision-making and practice updates. #### Where does this information come from? This content is from the CED Clinic, a source focused on cannabis and clinical education. It appears to be part of a structured clinical alert system designed to keep [healthcare professionals](https://cedclinic.com/women-reproductive-health-cannabis-applications/) informed about relevant developments. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).